Patient identification of the symptomatic impact of charcot-marie-tooth disease type 1A.
about
Recommendations to enable drug development for inherited neuropathies: Charcot-Marie-Tooth and Giant Axonal Neuropathy.Quality-of-life in Charcot-Marie-Tooth disease: the patient's perspective.Patient-identified impact of symptoms in spinal and bulbar muscular atrophy.What Matters Most: A Perspective From Adult Spinal Muscular Atrophy Patients.
P2860
Patient identification of the symptomatic impact of charcot-marie-tooth disease type 1A.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on September 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Patient identification of the symptomatic impact of charcot-marie-tooth disease type 1A.
@en
Patient identification of the symptomatic impact of charcot-marie-tooth disease type 1A.
@nl
type
label
Patient identification of the symptomatic impact of charcot-marie-tooth disease type 1A.
@en
Patient identification of the symptomatic impact of charcot-marie-tooth disease type 1A.
@nl
prefLabel
Patient identification of the symptomatic impact of charcot-marie-tooth disease type 1A.
@en
Patient identification of the symptomatic impact of charcot-marie-tooth disease type 1A.
@nl
P2093
P2860
P1476
Patient identification of the symptomatic impact of charcot-marie-tooth disease type 1A.
@en
P2093
Chad R Heatwole
David N Herrmann
Janet E Sowden
Michele Ferguson
Nicholas E Johnson
Shanie Jeanat
P2860
P356
10.1097/CND.0B013E31829E22E3
P577
2013-09-01T00:00:00Z